Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy

• Published in: Neurology. Genetics 2024-06, Vol.10 (3), p.e200148
• Main Authors: Foley, A Reghan, Yun, Pomi, Leach, Meganne E, Neuhaus, Sarah B, Averion, Gilberto V, Hu, Ying, Hayes, Leslie H, Donkervoort, Sandra, Jain, Minal S, Waite, Melissa, Parks, Rebecca, Bharucha-Goebel, Diana X, Mayer, Oscar H, Zou, Yaqun, Fink, Margaret, DeCoster, Jameice, Mendoza, Christopher, Arévalo, Cynthia, Hausmann, Rudolf, Petraki, Diana, Cheung, Ken, Bönnemann, Carsten G
• Format: Article
• Language: English
• ISSN: 2376-7839; 2376-7839
• DOI: 10.1212/NXG.0000000000200148

Omigapil is a small molecule which inhibits the GAPDH-Siah1-mediated apoptosis pathway. Apoptosis is a pathomechanism underlying the congenital muscular dystrophy subtypes LAMA2-related dystrophy (LAMA2-RD) and COL6-related dystrophy (COL6-RD). Studies of omigapil in the (dy /dy ) LAMA2-RD mouse model demonstrated improved survival, and studies in the (dy /dy ) LAMA2-RD mouse model and the (Col6a1 ) COL6-RD mouse model demonstrated decreased apoptosis. A phase 1 open-label, sequential group, ascending oral dose, cohort study of omigapil in patients with LAMA2-RD or COL6-RD ages 5-16 years was performed (1) to establish the pharmacokinetic (PK) profile of omigapil at a range of doses, (2) to evaluate the safety and tolerability of omigapil at a range of doses, and (3) to establish the feasibility of conducting disease-relevant clinical assessments. Patients were enrolled in cohorts of size 4, with each patient receiving 4 weeks of vehicle run-in and 12 weeks of study drug (at daily doses ranging from 0.02 to 0.08 mg/kg). PK data from each cohort were analyzed before each subsequent dosing cohort was enrolled. A novel, adaptive dose-finding method (stochastic approximation with virtual observation recursion) was used to allow for dose escalation/reduction between cohorts based on PK data. Twenty patients were enrolled at the NIH (LAMA2-RD: N = 10; COL6-RD: N = 10). Slightly greater than dose-proportional increases in systemic exposure to omigapil were seen at doses 0.02-0.08 mg/kg/d. The dose which achieved patient exposure within the pre-established target area under the plasma concentration-vs-time curve (AUC ) range was 0.06 mg/kg/d. In general, omigapil was safe and well tolerated. No consistent changes were seen in the disease-relevant clinical assessments during the duration of the study. This study represents the thus far only clinical trial of a therapeutic small molecule for LAMA2-RD and COL6-RD, completed with an adaptive trial design to arrive at dose adjustments. The trial met its primary end point and established that the PK profile of omigapil is suitable for further development in pediatric patients with LAMA2-RD or COL6-RD, the most common forms of congenital muscular dystrophy. While within the short duration of the study disease-relevant clinical assessments did not demonstrate significant changes, this study establishes the feasibility of performing interventional clinical trials in these rare disease patient populations. This study provid